| Platelet activation in unstable coronary disease DJ Fitzgerald, L Roy, F Catella, GA FitzGerald New England Journal of Medicine 315 (16), 983-989, 1986 | 1496 | 1986 |
| Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions JA Coppinger, G Cagney, S Toomey, T Kislinger, O Belton, ... Blood 103 (6), 2096-2104, 2004 | 1060 | 2004 |
| Ticlopidine and clopidogrel MJ Quinn, DJ Fitzgerald Circulation 100 (15), 1667-1672, 1999 | 755 | 1999 |
| The relationship between cyclooxygenase-2 expression and colorectal cancer KM Sheehan, K Sheahan, DP O'Donoghue, F MacSweeney, RM Conroy, ... Jama 282 (13), 1254-1257, 1999 | 708 | 1999 |
| Expert consensus document on the use of antiplatelet agents: The Task Force on the Use of Antiplatelet Agents in Patients With Atherosclerotic Cardiovascular Disease of the … C Patrono, F Bachmann, C Baigent, C Bode, R De Caterina, ... European heart journal 25 (2), 166-181, 2004 | 688 | 2004 |
| Cyclooxygenase-1 and-2–dependent prostacyclin formation in patients with atherosclerosis O Belton, D Byrne, D Kearney, A Leahy, DJ Fitzgerald Circulation 102 (8), 840-845, 2000 | 553 | 2000 |
| Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. DJ Fitzgerald, F Catella, L Roy, GA FitzGerald Circulation 77 (1), 142-150, 1988 | 533 | 1988 |
| Oxidative damage of cardiomyocytes is limited by extracellular regulated kinases 1/2-mediated induction of cyclooxygenase-2 SR Adderley, DJ Fitzgerald Journal of Biological Chemistry 274 (8), 5038-5046, 1999 | 487 | 1999 |
| Multiple mechanisms for the activation of human platelet aggregation by Staphylococcus aureus: roles for the clumping factors ClfA and ClfB, the serine–aspartate … L O´ Brien, SW Kerrigan, G Kaw, M Hogan, J Penadés, D Litt, ... Molecular microbiology 44 (4), 1033-1044, 2002 | 411 | 2002 |
| Integration of proteomics and genomics in platelets: a profile of platelet proteins and platelet-specific genes JP McRedmond, SD Park, DF Reilly, JA Coppinger, PB Maguire, ... Molecular & Cellular Proteomics 3 (2), 133-144, 2004 | 391 | 2004 |
| Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers D Cox, AO Maree, M Dooley, R Conroy, MF Byrne, DJ Fitzgerald Stroke 37 (8), 2153-2158, 2006 | 355 | 2006 |
| Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease AO Maree, RJ Curtin, M Dooley, RM Conroy, P Crean, D Cox, ... Journal of the American College of Cardiology 46 (7), 1258-1263, 2005 | 343 | 2005 |
| 8-Epi PGF2α Generation During Coronary Reperfusion: A Potential Quantitative Marker of Oxidant Stress In Vivo N Delanty, MP Reilly, D Pratico, JA Lawson, JF McCarthy, AE Wood, ... Circulation 95 (11), 2492-2499, 1997 | 343 | 1997 |
| Decreased prostacyclin biosynthesis preceding the clinical manifestation of pregnancy-induced hypertension. DJ Fitzgerald, SS Entman, K Mulloy, GA FitzGerald Circulation 75 (5), 956-963, 1987 | 335 | 1987 |
| Cyclooxygenase‐1 haplotype modulates platelet response to aspirin AO Maree, RJ Curtin, A Chubb, C Dolan, D Cox, J O'brien, P Crean, ... Journal of Thrombosis and Haemostasis 3 (10), 2340-2345, 2005 | 333 | 2005 |
| Hematopoietic prostaglandin D2 synthase controls the onset and resolution of acute inflammation through PGD2 and 15-deoxyΔ12–14 PGJ2 R Rajakariar, M Hilliard, T Lawrence, S Trivedi, P Colville-Nash, ... Proceedings of the National Academy of Sciences 104 (52), 20979-20984, 2007 | 316 | 2007 |
| Variable platelet response to aspirin and clopidogrel in atherothrombotic disease AO Maree, DJ Fitzgerald Circulation 115 (16), 2196-2207, 2007 | 298 | 2007 |
| Milk‐derived bioactive peptides and their health promoting effects: a potential role in atherosclerosis S Marcone, O Belton, DJ Fitzgerald British journal of clinical pharmacology 83 (1), 152-162, 2017 | 281 | 2017 |
| Thromboxane A2 synthesis in pregnancy-induced hypertension DJ Fitzgerald, W Rocki, R Murray, G Mayo, GA FitzGerald The Lancet 335 (8692), 751-754, 1990 | 277 | 1990 |
| Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease EJ Topol, D Easton, RA Harrington, P Amarenco, RM Califf, C Graffagnino, ... Circulation 108 (4), 399-406, 2003 | 275 | 2003 |
